Monday, October 05, 2015 6:10:32 AM
Good results in Pivotal P2B Clinical Trial potentially often result in FDA advanced Commercial approvals for medical therapies for unmet medical needs where often death within 6 to 12 months is the case with current ineffective therapies.
Pivotal P2B agreed Protocol always take the longest to get the FDA full agreement. Often 6 to 9 months with back and forth FDA discussions. In the several Pharmas that I track with Pivotal P2Bs, the exact situation is going on with lengthy delays. Shareholders become frustrated as Shorts attack the PPS.
It is the time for Investors to do deeper DD, and for those that do IMO, it is a great opportunity to add more shares on the cheap.
$ONCS Combo Pivotal P2B with MRK's Keytruda has been underway since July/Aug and apparently UCSF has undertake total sponsorship for the 41 person Clinical Trial.
https://clinicaltrials.gov/ct2/show/NCT02493361?term=UCSF+and+keytruda&rank=2
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM